Clinical trial of focal segmental glomerulosclerosis in children and young adults

Debbie S. Gipson, Howard Trachtman, Frederick J. Kaskel, Tom H. Greene, Milena K. Radeva, Jennifer J. Gassman, Marva M. Moxey-Mims, Ronald J. Hogg, Sandra L. Watkins, Richard N. Fine, Susan L. Hogan, John P. Middleton, V. Matti Vehaskari, Patti A. Flynn, Leslie M. Powell, Suzanne M. Vento, June L. McMahan, Norman Siegel, Vivette D. D'Agati, Aaron L. Friedman

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

This NIH-funded multicenter randomized study of focal segmental glomerulosclerosis (FSGS) treatment compared the efficacy of a 12-month course of cyclosporine to a combination of oral pulse dexamethasone and mycophenolate mofetil in children and adults with steroid-resistant primary FSGS. Of the 192 patients enrolled, 138 were randomized to cyclosporine (72) or to mycophenolate/dexamethasone (66). The primary analysis compared the levels of an ordinal variable measuring remission during the first year. The odds ratio (0.59) for achieving at least a partial remission with mycophenolate/ dexamethasone compared to cyclosporine was not significant. Partial or complete remission was achieved in 22 mycophenolate/dexamethasone- and 33 cyclosporine-treated patients at 12 months. The main secondary outcome, preservation of remission for 26 weeks following cessation of treatment, was not significantly different between these two therapies. During the entire 78 weeks of study, 8 patients treated with cyclosporine and 7 with mycophenolate/ dexamethasone died or developed kidney failure. Thus, our study did not find a difference in rates of proteinuria remission following 12 months of cyclosporine compared to mycophenolate/dexamethasone in patients with steroid-resistant FSGS. However, the small sample size might have prevented detection of a moderate treatment effect.

Original languageEnglish (US)
Pages (from-to)868-878
Number of pages11
JournalKidney International
Volume80
Issue number8
DOIs
StatePublished - Oct 2 2011
Externally publishedYes

Fingerprint

Focal Segmental Glomerulosclerosis
Dexamethasone
Cyclosporine
Young Adult
Clinical Trials
Steroids
Mycophenolic Acid
Withholding Treatment
Proteinuria
Sample Size
Multicenter Studies
Renal Insufficiency
Odds Ratio
Therapeutics

Keywords

  • focal segmental glomerulosclerosis
  • proteinuria
  • randomized controlled trial

ASJC Scopus subject areas

  • Nephrology

Cite this

Gipson, D. S., Trachtman, H., Kaskel, F. J., Greene, T. H., Radeva, M. K., Gassman, J. J., ... Friedman, A. L. (2011). Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney International, 80(8), 868-878. https://doi.org/10.1038/ki.2011.195

Clinical trial of focal segmental glomerulosclerosis in children and young adults. / Gipson, Debbie S.; Trachtman, Howard; Kaskel, Frederick J.; Greene, Tom H.; Radeva, Milena K.; Gassman, Jennifer J.; Moxey-Mims, Marva M.; Hogg, Ronald J.; Watkins, Sandra L.; Fine, Richard N.; Hogan, Susan L.; Middleton, John P.; Vehaskari, V. Matti; Flynn, Patti A.; Powell, Leslie M.; Vento, Suzanne M.; McMahan, June L.; Siegel, Norman; D'Agati, Vivette D.; Friedman, Aaron L.

In: Kidney International, Vol. 80, No. 8, 02.10.2011, p. 868-878.

Research output: Contribution to journalArticle

Gipson, DS, Trachtman, H, Kaskel, FJ, Greene, TH, Radeva, MK, Gassman, JJ, Moxey-Mims, MM, Hogg, RJ, Watkins, SL, Fine, RN, Hogan, SL, Middleton, JP, Vehaskari, VM, Flynn, PA, Powell, LM, Vento, SM, McMahan, JL, Siegel, N, D'Agati, VD & Friedman, AL 2011, 'Clinical trial of focal segmental glomerulosclerosis in children and young adults', Kidney International, vol. 80, no. 8, pp. 868-878. https://doi.org/10.1038/ki.2011.195
Gipson, Debbie S. ; Trachtman, Howard ; Kaskel, Frederick J. ; Greene, Tom H. ; Radeva, Milena K. ; Gassman, Jennifer J. ; Moxey-Mims, Marva M. ; Hogg, Ronald J. ; Watkins, Sandra L. ; Fine, Richard N. ; Hogan, Susan L. ; Middleton, John P. ; Vehaskari, V. Matti ; Flynn, Patti A. ; Powell, Leslie M. ; Vento, Suzanne M. ; McMahan, June L. ; Siegel, Norman ; D'Agati, Vivette D. ; Friedman, Aaron L. / Clinical trial of focal segmental glomerulosclerosis in children and young adults. In: Kidney International. 2011 ; Vol. 80, No. 8. pp. 868-878.
@article{6e9decdda5ff485aab1faed59b409506,
title = "Clinical trial of focal segmental glomerulosclerosis in children and young adults",
abstract = "This NIH-funded multicenter randomized study of focal segmental glomerulosclerosis (FSGS) treatment compared the efficacy of a 12-month course of cyclosporine to a combination of oral pulse dexamethasone and mycophenolate mofetil in children and adults with steroid-resistant primary FSGS. Of the 192 patients enrolled, 138 were randomized to cyclosporine (72) or to mycophenolate/dexamethasone (66). The primary analysis compared the levels of an ordinal variable measuring remission during the first year. The odds ratio (0.59) for achieving at least a partial remission with mycophenolate/ dexamethasone compared to cyclosporine was not significant. Partial or complete remission was achieved in 22 mycophenolate/dexamethasone- and 33 cyclosporine-treated patients at 12 months. The main secondary outcome, preservation of remission for 26 weeks following cessation of treatment, was not significantly different between these two therapies. During the entire 78 weeks of study, 8 patients treated with cyclosporine and 7 with mycophenolate/ dexamethasone died or developed kidney failure. Thus, our study did not find a difference in rates of proteinuria remission following 12 months of cyclosporine compared to mycophenolate/dexamethasone in patients with steroid-resistant FSGS. However, the small sample size might have prevented detection of a moderate treatment effect.",
keywords = "focal segmental glomerulosclerosis, proteinuria, randomized controlled trial",
author = "Gipson, {Debbie S.} and Howard Trachtman and Kaskel, {Frederick J.} and Greene, {Tom H.} and Radeva, {Milena K.} and Gassman, {Jennifer J.} and Moxey-Mims, {Marva M.} and Hogg, {Ronald J.} and Watkins, {Sandra L.} and Fine, {Richard N.} and Hogan, {Susan L.} and Middleton, {John P.} and Vehaskari, {V. Matti} and Flynn, {Patti A.} and Powell, {Leslie M.} and Vento, {Suzanne M.} and McMahan, {June L.} and Norman Siegel and D'Agati, {Vivette D.} and Friedman, {Aaron L.}",
year = "2011",
month = "10",
day = "2",
doi = "10.1038/ki.2011.195",
language = "English (US)",
volume = "80",
pages = "868--878",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Clinical trial of focal segmental glomerulosclerosis in children and young adults

AU - Gipson, Debbie S.

AU - Trachtman, Howard

AU - Kaskel, Frederick J.

AU - Greene, Tom H.

AU - Radeva, Milena K.

AU - Gassman, Jennifer J.

AU - Moxey-Mims, Marva M.

AU - Hogg, Ronald J.

AU - Watkins, Sandra L.

AU - Fine, Richard N.

AU - Hogan, Susan L.

AU - Middleton, John P.

AU - Vehaskari, V. Matti

AU - Flynn, Patti A.

AU - Powell, Leslie M.

AU - Vento, Suzanne M.

AU - McMahan, June L.

AU - Siegel, Norman

AU - D'Agati, Vivette D.

AU - Friedman, Aaron L.

PY - 2011/10/2

Y1 - 2011/10/2

N2 - This NIH-funded multicenter randomized study of focal segmental glomerulosclerosis (FSGS) treatment compared the efficacy of a 12-month course of cyclosporine to a combination of oral pulse dexamethasone and mycophenolate mofetil in children and adults with steroid-resistant primary FSGS. Of the 192 patients enrolled, 138 were randomized to cyclosporine (72) or to mycophenolate/dexamethasone (66). The primary analysis compared the levels of an ordinal variable measuring remission during the first year. The odds ratio (0.59) for achieving at least a partial remission with mycophenolate/ dexamethasone compared to cyclosporine was not significant. Partial or complete remission was achieved in 22 mycophenolate/dexamethasone- and 33 cyclosporine-treated patients at 12 months. The main secondary outcome, preservation of remission for 26 weeks following cessation of treatment, was not significantly different between these two therapies. During the entire 78 weeks of study, 8 patients treated with cyclosporine and 7 with mycophenolate/ dexamethasone died or developed kidney failure. Thus, our study did not find a difference in rates of proteinuria remission following 12 months of cyclosporine compared to mycophenolate/dexamethasone in patients with steroid-resistant FSGS. However, the small sample size might have prevented detection of a moderate treatment effect.

AB - This NIH-funded multicenter randomized study of focal segmental glomerulosclerosis (FSGS) treatment compared the efficacy of a 12-month course of cyclosporine to a combination of oral pulse dexamethasone and mycophenolate mofetil in children and adults with steroid-resistant primary FSGS. Of the 192 patients enrolled, 138 were randomized to cyclosporine (72) or to mycophenolate/dexamethasone (66). The primary analysis compared the levels of an ordinal variable measuring remission during the first year. The odds ratio (0.59) for achieving at least a partial remission with mycophenolate/ dexamethasone compared to cyclosporine was not significant. Partial or complete remission was achieved in 22 mycophenolate/dexamethasone- and 33 cyclosporine-treated patients at 12 months. The main secondary outcome, preservation of remission for 26 weeks following cessation of treatment, was not significantly different between these two therapies. During the entire 78 weeks of study, 8 patients treated with cyclosporine and 7 with mycophenolate/ dexamethasone died or developed kidney failure. Thus, our study did not find a difference in rates of proteinuria remission following 12 months of cyclosporine compared to mycophenolate/dexamethasone in patients with steroid-resistant FSGS. However, the small sample size might have prevented detection of a moderate treatment effect.

KW - focal segmental glomerulosclerosis

KW - proteinuria

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=80053490859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053490859&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.195

DO - 10.1038/ki.2011.195

M3 - Article

VL - 80

SP - 868

EP - 878

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 8

ER -